217 related articles for article (PubMed ID: 14668459)
1. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
[No Abstract] [Full Text] [Related]
2. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
4. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
6. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
7. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
10. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of pediatric hypereosinophilic syndrome with suplatast tosilate.
Yamada Y; Yoshihara S; Arisaka O
Ann Allergy Asthma Immunol; 2007 Oct; 99(4):380-1. PubMed ID: 17941289
[No Abstract] [Full Text] [Related]
14. Combating the eosinophil with anti-interleukin-5 therapy.
Wechsler ME
N Engl J Med; 2008 Mar; 358(12):1293-4. PubMed ID: 18344569
[No Abstract] [Full Text] [Related]
15. Selective priming of peripheral blood eosinophils in patients with idiopathic hypereosinophilic syndrome.
Lampinen M; Oberg G; Venge P; Carlson M
APMIS; 2006 Nov; 114(11):757-63. PubMed ID: 17078855
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
18. Infliximab as a therapy for idiopathic hypereosinophilic syndrome.
Taverna JA; Lerner A; Goldberg L; Werth S; Demierre MF
Arch Dermatol; 2007 Sep; 143(9):1110-2. PubMed ID: 17875870
[No Abstract] [Full Text] [Related]
19. Hypereosinophilic syndrome and mepolizumab.
Boucher RM; Gilbert-McClain L; Chowdhury B
N Engl J Med; 2008 Jun; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
[No Abstract] [Full Text] [Related]
20. Hypereosinophilic syndrome and mepolizumab.
Verzegnassi F
N Engl J Med; 2008 Jun; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
